BIOMAT Database Logo BIOMAT Database Logo

Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. 1999

D R Kuritzkes, and I Marschner, and V A Johnson, and R Bassett, and J J Eron, and M A Fischl, and R L Murphy, and K Fife, and J Maenza, and M E Rosandich, and D Bell, and K Wood, and J P Sommadossi, and C Pettinelli
University of Colorado Health Sciences Center and Veterans Affairs Medical Center, Denver 80262, USA.

OBJECTIVE To study the antiviral activity of lamivudine (3TC) plus zidovudine (ZDV), didanosine (ddl), or stavudine (d4T). METHODS Randomized, placebo-controlled, partially double-blinded multicenter study. METHODS Adult AIDS Clinical Trials Units. METHODS Treatment-naive HIV-infected adults with 200-600x10(6) CD4 T lymphocytes/l. METHODS Patients were openly randomized to a d4T or a ddl limb, then randomized in a blinded manner to receive: d4T (80 mg/day), d4T plus 3TC (300 mg/day), or ZDV (600 mg/day) plus 3TC, with matching placebos; or ddl (400 mg/day), ddl plus 3TC (300 mg/day), or ZDV (600 mg/day) plus 3TC, with matching placebos. After 24 weeks 3TC was added for patients assigned to the monotherapy arms. METHODS The reduction in plasma HIV-1 RNA level at weeks 24 and 48. RESULTS Two hundred ninety-nine patients were enrolled. After 24 weeks the mean reduction in plasma HIV-1 RNA copies/ml from baseline was 0.49 log10 (d4T monotherapy) versus 1.03 log10 (d4T plus 3TC; P = 0.001), and 0.68 log10 (ddl monotherapy) versus 0.82 log10 (ddl plus 3TC; P>0.22). After 48 weeks the mean reduction was 1.08 log10 (d4T plus 3TC) versus 1.01 log10 (ZDV plus 3TC) in the d4T limb (P = 0.66), and 0.94 log10 (ddl plus 3TC) versus 0.88 log10 (ZDV plus 3TC; P = 0.70) in the ddl limb. CONCLUSIONS 3TC added significantly to the virologic effects of d4T, but not ddl, in treatment-naive patients. 3TC plus d4T produced virologic changes comparable to those of 3TC plus ZDV. These results support the use of 3TC with either ZDV or d4 as a component of initial combination antiretroviral therapy.

UI MeSH Term Description Entries
D008297 Male Males
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

D R Kuritzkes, and I Marschner, and V A Johnson, and R Bassett, and J J Eron, and M A Fischl, and R L Murphy, and K Fife, and J Maenza, and M E Rosandich, and D Bell, and K Wood, and J P Sommadossi, and C Pettinelli
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
June 1996, Annals of internal medicine,
D R Kuritzkes, and I Marschner, and V A Johnson, and R Bassett, and J J Eron, and M A Fischl, and R L Murphy, and K Fife, and J Maenza, and M E Rosandich, and D Bell, and K Wood, and J P Sommadossi, and C Pettinelli
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
January 1999, Antimicrobial agents and chemotherapy,
D R Kuritzkes, and I Marschner, and V A Johnson, and R Bassett, and J J Eron, and M A Fischl, and R L Murphy, and K Fife, and J Maenza, and M E Rosandich, and D Bell, and K Wood, and J P Sommadossi, and C Pettinelli
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
August 1996, Annals of internal medicine,
D R Kuritzkes, and I Marschner, and V A Johnson, and R Bassett, and J J Eron, and M A Fischl, and R L Murphy, and K Fife, and J Maenza, and M E Rosandich, and D Bell, and K Wood, and J P Sommadossi, and C Pettinelli
Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.
March 1997, Annals of internal medicine,
D R Kuritzkes, and I Marschner, and V A Johnson, and R Bassett, and J J Eron, and M A Fischl, and R L Murphy, and K Fife, and J Maenza, and M E Rosandich, and D Bell, and K Wood, and J P Sommadossi, and C Pettinelli
Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
May 1995, Archives of internal medicine,
D R Kuritzkes, and I Marschner, and V A Johnson, and R Bassett, and J J Eron, and M A Fischl, and R L Murphy, and K Fife, and J Maenza, and M E Rosandich, and D Bell, and K Wood, and J P Sommadossi, and C Pettinelli
A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
October 1998, The Journal of pediatrics,
D R Kuritzkes, and I Marschner, and V A Johnson, and R Bassett, and J J Eron, and M A Fischl, and R L Murphy, and K Fife, and J Maenza, and M E Rosandich, and D Bell, and K Wood, and J P Sommadossi, and C Pettinelli
Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
October 1995, Annals of internal medicine,
D R Kuritzkes, and I Marschner, and V A Johnson, and R Bassett, and J J Eron, and M A Fischl, and R L Murphy, and K Fife, and J Maenza, and M E Rosandich, and D Bell, and K Wood, and J P Sommadossi, and C Pettinelli
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
August 1992, The New England journal of medicine,
D R Kuritzkes, and I Marschner, and V A Johnson, and R Bassett, and J J Eron, and M A Fischl, and R L Murphy, and K Fife, and J Maenza, and M E Rosandich, and D Bell, and K Wood, and J P Sommadossi, and C Pettinelli
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
July 1996, JAMA,
D R Kuritzkes, and I Marschner, and V A Johnson, and R Bassett, and J J Eron, and M A Fischl, and R L Murphy, and K Fife, and J Maenza, and M E Rosandich, and D Bell, and K Wood, and J P Sommadossi, and C Pettinelli
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
May 1990, Annals of internal medicine,
Copied contents to your clipboard!